Moreover, to address the question regarding which group is associated with superior clinical protection against COVID-19, further studies involving pharmacokinetic aspects, such as IgG3 half-life and the stability of this isotype in the blood of this pediatric population, as well as correlations between clinical features and antibody functionality, would be valuable in determining whether mRNA vaccination confers superior protection than SARS-CoV-2 infection. This evidence concerns the gene IGHG3 and COVID-19.